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Abstract
Diabetes mellitus is one of the most common diseases, with a 200% predicted increase in
prevalence over the next several decades (Kadoi, 2010). With a known increase in
perioperative risk, diabetic patients present with multiple comorbidities that must be
considered when adopting an anesthetic plan (Kadoi, 2010). One of the most common
complications affecting approximately 50% of patients, is gastroparesis resulting from
the development of diabetic autonomic neuropathy. Gastroparesis places the diabetic
patient at an increased risk of aspiration and also postoperative nausea and vomiting
(PONV). Dexamethasone is a glucocorticoid that is one of the most common
prophylactic antiemetics used to prevent PONV. Dexamethasone has been associated
with an increase in blood glucose levels which can be detrimental to the diabetic surgical
patient (Shaikh et al., 2016). The purpose of this systematic review was to investigate the
current literature and examine the impact of dexamethasone on blood glucose levels in
the adult diabetic surgical patient when used in the prevention of PONV. A
comprehensive literature review was completed using CINAHL and PubMed databases.
The physiology and perioperative management of diabetes and PONV, along with the
pharmacodynamics of dexamethasone was reviewed. Eligible studies were chosen based
on guidance from the PRISMA theoretical framework. Study analysis was completed by
constructing study specific and data outcome tables. Critical appraisal of individual
RCTs was conducted utilizing the Critical Appraisal Skills Programme (CASP) checklist.
A cross study analysis table was also developed comparing the results of all eligible
studies against one another. The findings of this systematic review concluded

dexamethasone 8mg IV was associated with an increase in perioperative blood glucose
levels, although, the increase may not have been statistically significant.
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The Use of Dexamethasone in the Adult Diabetic Surgical Population for the
Prevention of Postoperative Nausea and Vomiting: A Systematic Review
Background/Statement of the Problem
Diabetic patients present to surgery with independent risk factors. Patients
with hyperglycemia during the surgical period are at a greater risk for electrolyte
imbalances, dehydration, increased risk of infection, fluid shifts, compromised wound
healing, and ketoacidosis (Joshi et al., 2010). Diabetic patients often have other
associated comorbidities resulting from chronic inadequate blood glucose control.
Microvascular changes are often seen in the retinal and renal vessels, impacting sight and
kidney function. Peripheral neuropathy and increased infection risk also need to be taken
into consideration during the perioperative period. One of the most severe complications
associated with diabetes is the presence of autonomic neuropathy. Diabetic autonomic
neuropathy is a condition characterized by damage to small autonomic nerve fibers
resulting in greater decline in blood pressure and increased need of vasopressors in the
perioperative period. Other symptoms accompanying diabetic autonomic neuropathy
include hypotension associated with position changes, impotence, diarrhea, sweating
abnormalities and delayed gastric emptying. Diabetic patients with autonomic
neuropathy are at an elevated risk for postoperative nausea and vomiting (PONV) and
gastric aspiration due to gastroparesis (Miller et al., 2015).
PONV occur in 20% to 40% of all surgical patients and is the second most
common complaint secondary to pain (Cao et al., 2017). The occurrence of PONV can
delay recovery, prolong discharge, and result in unanticipated hospital admission. It also
places the patient at a higher risk of developing pulmonary aspiration, electrolyte
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imbalances, wound dehiscence, and dehydration. All of these complications result in
increased distress on the patient and increased medical costs (Shaikh et al., 2016).
Despite a considerable amount of research conducted and strategies developed,
there has not been a consensus on an optimal regimen to treat PONV. However, there
has been emphasis in literature and practice on the anticipatory rather than reactionary
treatment. Dexamethasone is a glucocorticoid steroid that is one of the most common
anticipatory antiemetics used. The use of dexamethasone is associated with potential
risks including impaired wound healing, increased blood glucose levels, and an increase
risk of infection (Miller et al., 2015). These risk factors make its use in the diabetic
population controversial. Therefore, this study examines the impact of dexamethasone
on blood glucose levels in the adult diabetic surgical patient when used in the prevention
of PONV.
Next, a literature review will be presented.
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Literature Review
A literature review was preformed to examine information about the use of
dexamethasone in diabetic patients to prevent PONV. Databases searched were PubMed,
Medline, CINAHL, and google scholar. Search words included dexamethasone, diabetes,
and postoperative nausea and vomiting. Randomized control trials, evidence-based
reviews, and guidelines were included in this literature review.
Diabetes Mellitus
In 2015, 30.3 million Americans had diabetes with an additional 1.5 million new
cases added each year (ADA, 2015). Diabetes was the seventh leading cause of death in
2015 (ADA, 2015) with a mortality rate three times higher than the average population
(Kadoi, 2010). Although, a diagnosis of diabetes is not an independent risk factor for the
development of PONV, approximately 50% of diabetic patients suffer from gastroparesis
or delayed gastric emptying. This delayed emptying can result in a cascade of injurious
events in which the increase in gastric volume can contribute to the development of
symptoms of nausea and vomiting, but also induce aspiration of gastric contents during
induction of anesthesia (Kadoi, 2010). With aspiration being the number one cause of
airway-related mortality for anesthesia providers, a probable increase in gastric contents
of diabetic patients prompts serious consideration and planning during the perioperative
period (Robinson & Davidson, 2014).
Pathophysiology. Diabetes Mellitus (DM) is a group of disorders sharing the
clinical feature of absolute or relative lack of insulin. DM is diagnosed with a fasting
blood glucose (BG) of greater than 110 mg/dL (6.1 mmol/L) (Miller et al, 2015).
Impaired glucose tolerance can be diagnosed with a fasting BG of 109 mg/dL – 100
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mg/dL (6.1 mmol/L – 5.5 mmol/L) (Miller et al, 2015). DM is characterized by multiple
metabolic abnormalities that can result in microvascular lesions and long-term end-organ
damage. The term “diabetes” can account for two different diseases that share the same
complication of end-organ damage: type 1 and type 2 (Miller et al, 2015).
Type 1 DM occurs when a patient is unable to produce insulin. Insulin is
produced in the pancreas by beta cells; these cells are susceptible to viral infections
and/or autoimmune disorders. Cellular metabolism is dependent on glucose metabolism
which is fielded by insulin. Lack of insulin production not only results in high glucose
levels but it also forces the body into generating alternative fuel. The alternative fuel
source can be derived from the breakdown of fats and proteins. An increase in keto acid
byproducts from the destruction of fats and proteins can result in the development of
ketoacidosis and lead to diabetic coma and death (Miller et al, 2015).
Type 2 DM results when there is a decreased response to insulin at the target
tissues. Type 2 diabetics account for 90 to 95% of all cases of diabetes. This disease has
a gradual onset and generally develops after the age of 30. The greatest risk factor for the
development of type 2 DM is obesity. The direct mechanism in which type 2 DM is
acquired is uncertain, however, it has been suggested that obese patients have fewer
insulin receptors. Another hypothesis suggests that due to increase lipid concentration,
signaling pathways between insulin and its receptors are interrupted (Hall, 2011).
Perioperative Blood Glucose Management. There is a lack of clear evidence to
suggest the optimal intraoperative glucose level, thus it remains unknown. The Society
for Ambulatory Anesthesia (SAMBA) published a consensus statement on diabetic
perioperative glucose management based on hospitalized surgical patient data and also
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the joint consensus statement from the American Association of Clinical
Endocrinologists (AACE) and American Diabetes Association (ADA) in 2010. SAMBA
recommends an individualized approach for glucose control; duration of surgery, degree
of surgical invasiveness, anesthetic choice, and expected time until resumption of
antidiabetic therapy must be considered. For the well-controlled diabetic patient,
intraoperative BG levels should be maintained <180 mg/dL (10.0 mmol/L). Poorly
controlled diabetics need a more modest approach to glucose control. Patients with
chronically elevated BG levels should be maintained around their preoperative baseline.
Chronic hyperglycemia results in the alteration of autoregulatory mechanisms.
Adaptations in the release of norepinephrine, epinephrine, cortisol, growth hormone, and
pancreatic polypeptides can occur. An acute drop in BG can result in symptomatic
hypoglycemia and organ dysfunction due to the body being accustomed to
hyperglycemia. An increase in the oxidative stress response can also occur. Such acute
fluctuations in the chronic hyperglycemic patient may increase morbidity and mortality,
perioperatively (Joshi et al., 2010).
Surgical Stress Response. Under times of stress and surgical stimulation, the
body responds to this stimulus with a wide range of endocrine, biochemical, and
metabolic reactions. The degree of response is in direct proportion to the stimuli. This
response is called the surgical stress response and although general anesthesia abolishes
awareness and perception, it does not suppress the coordinated response from the
autonomic nervous system and the neuro-endocrinal hormone system. These systems
release a variety of catabolic and anabolic hormones triggering a hypermetabolic state.
This state is generally well tolerated amongst healthy patients, however, in patient

6
populations with coronary artery disease, hypertension, aneurysmal disease, diabetes,
liver or renal disease these hypermetabolic changes increase mortality (Singh, 2003).
One of the main reactions to the stress response is stimulation of the
hypothalamus resulting in secretion of ACTH, which initiates a sudden increase of
cortisol, the main endogenous glucocorticoid. Cortisol has the ability to stimulate the
mobilization of amino acids to be converted into glucose, a process known as
gluconeogenesis (Singh, 2003). Cortisol also decreases glucose utilization by the cell,
further increasing hyperglycemia. Singh (2003) reports blood glucose levels can increase
by 50% from the preoperative normal.
To further increase hyperglycemia, Desborough (2000) describes an “insulin
resistant” state that also occurs during the perioperative phase. Insulin levels can
decrease after induction of anesthesia due to failure of secretion by beta cells of the
pancreas and also failure of cellular response to insulin (Desborough, 2000). Another
contribution to the hyperglycemic response to major surgery is the transient increase in
glucagon. Glucagon is a hormone produced by the alpha cells of the pancreas, which
promotes glycogenolysis, the breakdown of glycogen to glucose. Glucagon also
promotes gluconeogenesis, further increasing blood glucose levels (Desborough, 2000)
Regional anesthesia uses local anesthetics to produce a neural blockade which has
direct influence on the metabolic and endocrinal response. The inhibition of afferent and
efferent neural pathways prevents surgical stimulus from reaching the central nervous
system (Singh, 2003). Singh (2003) reports that a neuraxial blockade from T4 to S4
prevents the cortisol response during lower abdominal surgeries. In order to prevent the
insulin and glucagon response, a higher blockade from T2 to T6 is required, however,
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this level of blockade is often contradicted due detrimental alterations in cardiac function
that can occur (Singh, 2003).
Diabetic patients have been hypothesized to be in a chronic inflammatory state
when compared to nondiabetic healthy patients (Lin & Gletsu-Miller, 2012). This
chronic inflammatory state can be potentiated under surgical stress, leading to deleterious
outcomes (Lin & Gletsu-Miller, 2012). A study done by Lin and Gletsu-Miller (2012)
aimed to investigate the differences in the surgical stress response between diabetic and
nondiabetic patients undergoing laparoscopic Roux-en-Y gastric bypass by measuring
inflammatory cytokine levels. The study measured cytokine levels (IL-6, IL-10, and IL18) preoperatively and immediately after surgery in 39 morbidly obese patients (nine
with type 2 diabetes) and eight non-obese, normoglycemic patients (Lin & Gletsu-Miller,
2012). The results demonstrated an overall increase in in cytokine expression in the
diabetic and morbidly obese patients by several folds in comparison to the non-obese,
normoglycemic groups. At baseline, a higher IL-6 level was exhibited in the morbidly
obese group compared to the non-obese group (5.7 ± 1.3 pg/ml and 2.7 ± 0.6 pg/ml,
respectively, p < 0.05). The IL-6 response was induced highest amongst the diabetic,
obese group (78.9 ± 12.3 pg/ml); a modest response in the non-diabetic, obese group
(61.0 ± 5 pg/ml); and the lowest response in the non-obese group (36.3 ± 7.2 pg/ml) (p <
0.01). Consistent findings occurred with the IL-10 response. At baseline, the IL-10
levels were 1.5 ± 0.4 pg/ml, 1.2 ± 0.3, and 1.3 ± 0.3 pg/ml for non-diabetic, obese;
diabetic obese; and non-obese groups, respectively. The greatest IL-10 response
occurred in the obese, diabetic group (65.8 ± 1.9pg/ml, p < 0.001). The non-diabetic,
obese group and non-obese group levels were not significant but did increase post-
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operatively (15.1 ± 5.0 pg/ml and 8.5 ± 2.7pg/ml). It was found that preoperative IL-18
levels were significantly increased in the diabetic, obese patients (450.6 ± 56 pg/ml, p <
0.01) compared to the non-diabetic, obese group (297.8 ± 19pg/ml) and non-obese group
(286.6 ± 17pg/ml). However, post-operatively there was almost zero change to all three
groups (diabetic obese: 457.9 ± 64 pg/ml; non-diabetic obese: 300 ± 26 pg/ml; nonobese: 271 ± 31 pg/ml) (Lin & Gletsu-Miller, 2012). These results demonstrate a clear
increase in the surgical stress response in diabetic patients. An excessive or perpetual
inflammatory response can overwhelm the patient’s compensatory mechanisms,
potentiating multi-organ failure leading to demise (Lin & Gletsu-Miller, 2012). Careful
consideration must be made when choosing an anesthetic plan for a diabetic patient; the
use of an additional glucocorticoid, dexamethasone, can further increase cortisol levels
thus contributing to an increased surgical stress response.
Perioperative Risks. Perioperative risk factors vary based on individual health
practices and lifestyle choices. Diabetic patients undergoing surgery are at risk for
complications associated with end-organ dysfunction: renal insufficiency, cardiovascular
deterioration, joint and collagen tissue irregularities, neuropathies and inadequate
production of granulocytes (Grossman & Porth, 2014).
In a study done by Ghildiyal et al. (2016), perioperative hyperglycemia and the
incidence of postoperative infection was examined. The researchers conducted a
prospective study including 101 patients undergoing a variety of procedures. Random
blood sugars were taken preoperatively, intraoperatively, and postoperatively. A 30-day
postoperative follow-up was done evaluating for surgical wound infection, septicemia,
and urinary tract infections. Fifty-seven out of the 101 patients did have an incidence of
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hyperglycemia. The hyperglycemic patients developed infections at a rate of 26.3%
(15/57) compared to normoglycemic patients at 4.5% (2/44) (Ghildiyal et al., 2016).
In a retrospective cohort study performed by Guvener et al. (2002) aimed to
examine perioperative hyperglycemia and the incidence of postoperative infection in
diabetic patients undergoing coronary artery bypass grafting. The researchers examined
1090 adult charts, 400 out of 1090 patients had type 2 diabetes mellitus. The researchers
determined preoperative hyperglycemia to be the main risk factor for development of an
infection postoperatively. Twenty (5%) out of the 400 diabetic patients developed
postoperative infections which included: lung infections (0.5%), superficial sternal
wound infections (0.75%), infection of the donor site (1%), mediastinitis (1.25%), and
urinary tract infections (1.5%) (Guvener et al., 2002). It was also concluded diabetics
had a higher incidence of early mortality compared to nondiabetics (3% vs 1.73%, p =
0.048) (Guvener et al., 2002).
Likewise, a prospective study conducted by O’Sullivan et al. (2006) focused on
the impact of hemoglobin A1c (HbA1c) levels on adverse outcomes in non-diabetic and
diabetic patients undergoing elective and emergency vascular surgery. For six months
the researchers collected HbA1c levels on 165 patients. Patients were classified into four
groups determined by their plasma HbA1c levels: £ 6%, 6.1-7%, 7.1-8%, or > 8%.
Outcomes were determined on any cause of 30-day or 6-month morbidity and mortality.
Forty-three out of 165 (26.1%) patients had diabetes. The term “suboptimal” was used to
describe nondiabetic patients with HbA1c levels of > 6 to £ 7% and diabetic patients with
HbA1c levels of > 7% (O’Sullivan et al., 2006). The researchers concluded the
suboptimal non-diabetic patients had significantly higher rates of general 30-day
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morbidity versus patients with HbA1c levels of £ 6% (56.5% vs 15.7%, p < 0.001).
Correspondingly, when compared to diabetic patients with HgbA1c levels of £ 7%,
suboptimal diabetics with HbA1c levels of > 7% also had a higher rate of morbidity over
30 days (59.1% vs 19%, p = 0.018) (O’Sullivan et al., 2006). In conclusion, the
investigators determined, with a multivariate analysis, a suboptimal HbA1c may infer
prognostic significance in patients enduring vascular surgery (O’Sullivan et al., 2006).
Due to the increased rate of morbidity related to hyperglycemia, perioperative blood
sugar management becomes an essential part of anesthetic care. The use of
dexamethasone has shown deleterious effects on blood sugars (Joshi et al., 2010),
therefore this study evaluates its use for PONV in the diabetic patient and the effects on
blood sugar levels.
Diabetic Autonomic Neuropathy and Gastroparesis. According to gastric
emptying studies done using radio isotopic techniques, approximately 50% of insulin
dependent diabetic patients acquire autonomic neuropathy that results in impaired gastric
emptying (Kadoi, 2010). Neuropathy is caused by two mechanisms. The first
mechanism is related to vascular thickening which causes neural ischemia and
dysfunction. The second mechanism is due to Schwann cell demyelination leading to
slow neural conductance. Neuropathy can be of somatic nature, which usually occurs
first. The patient experiences the loss of proprioception, touch, and sensation (Grossman
& Porth, 2014). Autonomic neuropathy affects both the sympathetic and
parasympathetic nervous systems. Sympathetic denervation affects small arterioles; the
nerves are either absent or located at a distance from the arteriole. Vagal impairment can
be manifested by a decrease in cardiac response and decreased parasympathetic tone.
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This decline in vagal function leads to postural hypotension, sweating abnormalities,
impotence, diarrhea or gastroparesis. There is a 5-year mortality rate of greater than 50%
when a patient develops gastroparesis or postural hypotension (Miller et al., 2015).
Diabetic patients with autonomic neuropathy are at an elevated risk for PONV and gastric
aspiration due to gastroparesis. This is of clinical significance when diabetic patients
present for surgery, specifically emergency procedures in which they have not been
fasting (Miller et al., 2015). A case report published by Tokumine et al. (2005) discussed
a 28-year-old patient with a history of type I diabetes since age 12. The patient presented
for an elective eye procedure and had been fasting for 12 hours. Upon induction of
anesthesia the patient vomited and aspirated stomach contents that he had consumed 24
hours prior to surgery (Tokumine et al., 2005). The authors report that 30% of patients
with type II diabetes and 58% of patients with type I diabetes have impaired gastric
emptying. Consideration of delayed gastric transport having the potential to increase the
incidence of PONV, coupled with an increased risk of aspiration of gastric contents is
imperative knowledge when developing an anesthetic plan for diabetic patients
(Tokumine et al., 2005).
Postoperative Nausea Vomiting
Physiology. Postoperative nausea and vomiting develop when an ill-defined area
in the brain known as the “vomiting center” is stimulated by one or more of the five
primary afferent neuronal pathways: the chemoreceptor trigger zone (CRTZ), the vagal
afferents of the gastrointestinal tract, the vestibular system pathway, cerebral cortex
afferent pathway, and afferents from the midbrain. Stimulation of one or more of these
pathways occurs via activation of muscarinic, histamine, dopamine, or serotonin

12
receptors (Shaikh et al., 2016). The CRTZ lacks the blood brain barrier, allowing for
interaction and detection of emetogenic substances by the central nervous system via the
bloodstream. Apomorphine and opioids act on this area via serotonin (5hydroxytryptamine [5-HT]), dopamine (D2), M3- muscarinic, and histamine (H1)
receptors. (Miller et al., 2015). The vagal mucosal afferent pathway contains 5-HT, M3,
and H3 receptors. This pathway is stimulated by nitrous oxide, opioids, cardiac
glycosides, cytotoxic drugs, levodopa, bromocriptine, and ipecac (Shaikh et al., 2016).
The vestibular pathway contains H1 and muscarinic receptors, which are receptive to
nitrous oxide. This area is also stimulated heavily by positional changes, ear surgery, and
motion sickness. The cerebral cortex is fed and activated by emotions, fear, memory,
smell, sight, and taste. Nausea will result once the cerebral cortex has been stimulated in
such a manner. Lastly, the midbrain receives sensory information from the pharynx via
the gag reflex, esophagus, stomach, and upper portions of the small intestines which is
then conveyed to the vomiting center (Shaikh et al., 2016).
The vomiting center is located in the reticular formation in the brainstem (Shaikh
et al., 2016). Once stimulated, efferent motor signals are transferred via cranial nerves V,
VII, IX, X, and XII to the upper gastrointestinal (GI) tract. The lower GI tract is then
stimulated via cranial nerve X and sympathetic nerves. Signals are subsequently relayed
to the diaphragm and abdominal muscles via the spinal nerves initiating the act of
vomiting (Hall, 2011).
Risk Factors. There are many risk factors that can contribute to the development
of PONV. Apfel et al. (2012) conducted a systematic review in which 22 studies with a
total of 95,154 patients were included. The studies were pooled together to evaluate
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independent risk factors and other noncontributory factors. The researchers searched
PubMed, EMBASE, and Cochrane databases for any available evidence. They did not
restrict their search with any publication dates or language requirements. They also hand
searched the reference lists of the studies found. Three individual investigators
systematically evaluated the retrieved studies. Observational studies with more than 500
adults as well as randomized controlled trials were included. Data extraction was done
by one researcher and validated by a second individual investigator (Apfel et al., 2012).
Statistical analysis was performed with the Review Manager and bias in publication was
evaluated for all independent predictors with statistical significance. From the cohorts,
odd ratios (OR) were calculated by allotted point estimates for anesthesia related, patientspecific, and surgery related factors. There were five independent factors related to
anesthesia, eight patient specific factors, and 14 surgical risk factors identified (Apfel et
al., 2012).
Female gender was found to be the strongest patient-specific independent risk
factor with an OR of 2.57 (Apfel et al., 2012). The second strongest was having a history
of PONV and/or motion sickness (OR 2.09); followed by being a non-smoker (OR 1.82).
History of migraine was also found to be significant (OR 1.77). ASA status, BMI, and
age were not as significant (OR 1.21, 1.00, and 0.88 per decade, respectively) (Apfel et
al., 2012). Of the anesthesia related risk factors, volatile agents were found to have the
highest significance (OR 1.82). Next was the duration of anesthesia, per hour, (OR 1.46).
The use of nitrous oxide followed close behind (OR 1.45). The fourth and fifth
anesthesia related factors contributing to the development of PONV were the use of
opioids: postoperatively (OR 1.39) and intraoperatively (OR 1.03) (Apfel et al., 2012).
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The researchers identified 13 surgeries that contributed to PONV. The surgery with the
highest incidence of developing PONV was a cholecystectomy (1.90). Laparoscopic and
gynecologic procedures followed thereafter (OR 1.37 and 1.24, respectively). The other
surgeries that did not have clinical significance are: ENT, thyroid, ophthalmologic,
orthopedic, abdominal, plastic, neurological, and head and neck surgery (Apfel et al.,
2012).
Risk Assessment for PONV. To better facilitate identification of risk factors, it
is essential to assess individual patient’s risks for PONV. The two most frequently used
risk assessment tools for PONV are the Apfel score and the Koivuranta score (Gan et al.,
2014).
The Apfel scoring system was developed after data from two independent studies
were combined and cross analyzed (Apfel et al., 1999). A simplified risk score was
created and cross-validated with the original scores concluding the discriminating power
was not altered with the simplification. As a result, a final score was created consisting
of the following four predictors: female gender, history of PONV, history of motion
sickness, being a nonsmoker, and the use of opioids in the postoperative period (Apfel et
al., 1999). The presence of 0, 1, 2, 3, or 4 risk factors corresponds with the incidence of
PONV as 10%, 20%, 40%, 60%, and 80% respectively. Patients are scored as “low”,
“medium”, or “high” based on the number of risk factors they have; 0 – 1, 2, or 3,
respectfully (Gan et al., 2014).
The Koivuranta score was developed from a prospective interview-based survey
of 1107 inpatients. Each patient received a 78-item questionnaire that accompanied them
throughout their hospital stay. Information was collected regarding patient
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characteristics, presumed risk factors, details regarding the anesthetic and surgical
procedure, and occurrence of nausea and vomiting. The study determined the most
significant factors associated with an increased incidence of nausea and vomiting were:
female gender, history of PONV, extended duration of surgery, being a nonsmoker, and
history of motion sickness. Thus, the Koivuranta score was developed (Koivuranta et al.,
1997).
In a study done by van den Bosch et al. (2005) to validate the Apfel and
Koivuranta scoring systems, 1388 adult patients undergoing a variety of surgical
procedures were screened. The prognostic accuracy of each scoring system was
evaluated based on prediction of developing one episode of nausea and/or vomiting
within 24 hours postoperatively. This study determined that both scoring systems, based
on calibration and discrimination, were less accurate than anticipated compared to
previous studies. According to van den Bosch et al. (2005), both risk assessments
provided too extreme of prediction. Apfel’s area under the Receiver Operating
Characteristic curve (ROC area) was 0.63 and Koivuranta’s ROC area was determined to
be 0.66. The ROC area can range from discrimination equal to that of chance (0.5) to
perfect discrimination (1.0). These numbers are considerable, especially related to over
treatment, which can expose patients to unnecessary side-effects. This can be detrimental
in diabetic patients treated with dexamethasone if hyperglycemia ensues: poor wound
healing, dehydration, hyperosmolar states and increased risk of infection (Joshi et al.,
2010).
Management of PONV. The management of PONV requires an individualized
approach to each patient in which medical history, risk factors, cost-effectiveness must be
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considered. In 2014, SAMBA published consensus guidelines for the management of
PONV, highlighting the importance of combination therapy for PONV prophylaxis. It is
noted in the statement that combination regimens with optimal dosing have yet to be
established, however, the statement did include two algorithms based on individualized
risk factors (Gan et al., 2014). Each algorithm has suggestions for prophylactic
interventions and treatment of PONV. A risk assessment is conducted first for each
patient using either Koivuranta or Apfel scoring tool. Next, depending on provider
preference of implementing prophylactic measures, interventions are made based on
patients identified risk category. The first table (Table 1) does not provide an
intervention for patients identified as “low-risk”. For “medium-risk” patients, a two-drug
combination is recommended for prophylaxis; and a three-drug combination for “highrisk” patients. The second table (Table 2) provides prophylactic intervention for all
patients regardless of risk. Gan et al. (2014) does stress the drugs suggested for use in
each table are examples of interventions that could be used, however each patient’s
treatment plan must be individualized.
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Table 1
Risk-Adapted PONV-Prevention Algorithm (With No Prevention in Low-Risk Patients)
Estimated risk for PONV, as determined by a risk score
Low
Medium
High
Interventions
for prophylaxis

Interventions
for treatment

No preventions
(“wait and see”)

Drug A + Drug B or
TIVA

Drug A + Drug B +
TIVA
On a case -by-case
decision: further
interventions
1. Drug C
2. Drug D (in case of
ineffectiveness of
treatment in stage 1)

1. Drug B
1. Drug C
2. Drug C (in case
2. Drug D (in case of
of ineffectiveness
ineffectiveness of
of treatment in
treatment in stage 1)
stage 1)
Note. Example interventions for adult patients: Drug A = dexamethasone 4mg; Drug B =
ondansetron 4mg; Drug C = droperidol 1mg; Drug D = dimenhydrinate 1mg/kg. TIVA =
total intravenous anesthesia i.e. propofol induction and maintenance, without use of
nitrous oxide (Gan et al., 2014).
Table 2
PONV-Prevention Algorithm in All Patients Including Low-Risk Patients Plus Additional
Interventions for High-Risk Patients
Estimated risk for PONV, as determined by a risk score
Low
Medium
High
Interventions
Drug A + (Drug B
Drug A + (Drug B or
Drug A + Drug B +
for prophylaxis or TIVA)
TIVA)
TIVA
On a case -by-case
decision: further
interventions
Interventions
1. Drug C2. Drug D 1. Drug C
1. Drug C
for treatment
(in case of
2. Drug D (in case of
2. Drug D (in case of
ineffectiveness of
ineffectiveness of
ineffectiveness of
treatment in stage
treatment in stage 1)
treatment in stage 1)
1)
Note. Example interventions for adult patients: Drug A = dexamethasone 4mg; Drug B =
ondansetron 4mg; Drug C = droperidol 1mg; Drug D = dimenhydrinate 1mg/kg. TIVA =
total intravenous anesthesia i.e. propofol induction and maintenance, without use of
nitrous oxide (Gan et al., 2014).
A randomized, controlled trial was completed in 2004 by Apfel et al., in which
5,199 patients were enrolled for evaluation of treatment for postoperative nausea and
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vomiting. The trial was of factorial design in which as many as three antiemetic
interactions were evaluated. Of the patients enrolled, 4,123 subjects were randomly
allocated to 1 of 64 prophylactic interventions: no ondansetron or 4mg of ondansetron; no
dexamethasone or 4mg of dexamethasone; no droperidol or 1.25mg of droperidol;
volatile anesthetic or propofol; nitrous oxide or nitrogen; fentanyl or remifentanil. The
other patients were randomly assigned to one of the four first interventions (Apfel et al.,
2004). Nausea and vomiting 24 hours postoperatively were the primary outcome,
measured blindly. The study concluded dexamethasone, droperidol, and ondansetron
independently reduced the risk of PONV by approximately 26%. A 19% reduction in
risk was observed with the use of propofol and a 12% reduction with the use of nitrogen.
The combination of nitrogen and propofol (TIVA) were similar to the other antiemetics,
when used independently. The authors concluded that due to the variety of mechanisms
of actions of each antiemetic and similar effectiveness, the first choice should be based
on patient profile or the most cost-effective intervention. They also reported low risk
patients rarely need prophylaxis, a single intervention may be beneficial in patients with
moderate risk and high-risk patients should have multiple interventions (Apfel et al.,
2004).
In a meta-analysis done by Henzi et al. (2000) the use of dexamethasone for the
prevention of PONV was conducted using data from 17 trials with 1,946 patients
(children and adults). Analysis of the data revealed: 598 patients received
dexamethasone, 582 patients received either ondansetron, granisetron, droperiodol,
metoclopramide or perphenazine, 423 patients received a placebo; and 343 received a
combination of dexamethasone with either ondansetron or granisetron. With placebo, the
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incidence of early PONV (0 to 6 hours postoperatively) was 35%, and late PONV (0 to
24 hours postoperatively) was 50%. In order to prevent early and late vomiting in adult
patients, the researchers found 7.1 (95% CI 4.5 to 18) and 4.3 (2.3 to 2.6) was the number
needed to treat, respectively (Henzi et al., 2000). In examining the combination of
dexamethasone with a 5-HT3 receptor antagonist: ondansetron or granisetron, the number
needed to treat was 7.7 (4.8 to 19) compared to the 5-HT3 receptor antagonist alone at 7.8
(4.1 to 66). The data from the other antiemetic options were deemed incomparable and
therefore inconclusive. The researchers concluded the most optimal prophylactic
treatment regimen to prevent PONV in healthy patients was with a combination of
dexamethasone and a 5-HT3 receptor antagonist (Henzi et al., 2000).
The prophylactic management of PONV in diabetic surgical patients can be
complicated especially when the use of dexamethasone is widely popular. SAMBA’s
consensus statement regarding the management of diabetic patients undergoing
ambulatory surgery published in 2010 approves of the use of dexamethasone 4mg for
prophylactic treatment of PONV (Joshi et al., 2010). However, in 2014, SAMBA’s
consensus statement on the management of PONV undergoing ambulatory surgery
reports conflicting evidence regarding dexamethasone dosing and implications on BG
levels. This consensus statement reports dexamethasone use is relatively contraindicated
in labile diabetic patients (Gan et al., 2014). This current systematic review examines the
data regarding these statements and further evaluates the effects of dosing, 4mg or 8mg,
of dexamethasone on blood sugars postoperatively.
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Pharmacologic Antiemetic Classifications
Dopamine Antagonists. The two main dopamine antagonists are
metoclopramide and droperidol; however, haloperidol and perphenazine also used.
Metoclopramide promotes gastric motility, increases gastroesophageal sphincter tone,
and relaxes the pylorus and duodenum. It is also an antidopaminergic, with its ability to
cross the BBB and act on the CRTZ. However, due to its extrapyramidal side effects, it
is not used as frequently. Droperidol is a well-established antiemetic exerting its effects
on the GABA receptors in the CRTZ zone. This drug, however, has become
controversial since acquiring a black box warning for association of patients developing
torsades de pointes or severe arrhythmias due to QT prolongation (Miller et al., 2015).
Haloperidol is another dopamine agonist that is used as an antiemetic.
Haloperidol acts on the CRTZ and has been used commonly for nausea and sickness
caused by chemotherapy. It also has peripheral GI effects by relaxing the gastric
sphincter (Miller et al., 2015). Perphenazine is also a dopamine antagonist that is known
for its highly potent neuroleptic effect (Miller et al., 2015).
Histamine Antagonists. Two common antihistamines are meclizine and
promethazine. Both of these drugs antagonize histamine receptors. They also exert
effects on the vestibular apparatus by blocking acetylcholine receptors. Another
uncommon antihistamine used is, dimenhydrinate. This drug acts on the H1 receptor and
also has weak antimuscarinic activity. It has been used for the treatment of motion
sickness (Miller et al., 2015).
Anticholinergic Antagonists. Transdermal scopolamine exerts its effects on the
vestibular nuclei by inhibiting cholinergic transmission. It also works on the
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parasympathetic nervous system by way of competitive inhibition of muscarinic
receptors. It is used primarily for patients with a history of motion sickness.
Serotonin Antagonists. Agents such as ondansetron, dolasetron, palonosetron,
and granisetron are 5-HT antagonists that act centrally and also block vagal afferents
located in the gut.
Neurokinin- 1 Receptor (NK-1) Antagonists. Aprepitant, Cospitant, and
Rolapitant are part of a new group of antiemetics. Their mechanism of action is blocking
NK-1 receptors located in the NTS and areas in the reticular formation (Shaikh et al.,
2016).
Propofol. Propofol is a hypnotic-sedative that is frequently used for the induction
and maintenance of general anesthesia. It is also used in conjunction with regional
anesthesia, local anesthesia, and for monitored anesthesia care. It exerts its effects by
increasing chloride conductance at the GABAa receptor. Propofol has been found to have
anti-emetic properties and its use is recommended for reducing the baseline risk of
developing PONV. Sub-hypnotic doses of propofol have also been studied independently
for antiemetic properties (Gan et al., 1997).
Dexamethasone. The corticosteroid dexamethasone provides an antiemetic effect
by inhibiting the NTS in addition to inhibiting the synthesis of prostaglandins. The
blocking of prostaglandin synthesis results in better emesis control due to its effect on the
sensitization of emesis controlling neurotransmitters (Shaikh et al., 2016). In a study
performed by Wang et al. (2000) the minimum effective dose of dexamethasone was
examined in women undergoing a thyroidectomy. Two hundred seventeen women were
enrolled in a randomized, double-blinded, placebo-controlled study in which
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dexamethasone was administered at 10mg, 5mg, 2.5mg, 1.25mg, or saline. The results
concluded that the minimum effective dose of dexamethasone for preventing PONV is
5mg and there were no significant differences between the groups receiving 10mg doses
compared to 5mg doses. This finding can be clinically significant in mitigating the side
effects associated with the use of dexamethasone.
Additional uses for dexamethasone. The use of corticosteroids, specifically
dexamethasone, has been shown not only to be efficacious as an antiemetic, it has also
been shown to be successful in treating post-operative pain. A randomized, double-blind,
placebo-controlled study performed by Kardash et al. (2008) aimed to analyze the effects
of single-dose dexamethasone prior to total hip arthroplasty on dynamic pain. Prior to
surgery, fifty patients receiving propofol sedation with spinal anesthesia were placed into
two groups: group 1received 40mg of dexamethasone and group 2 received IV saline.
Postoperative pain was measured with the 0-10 numeric rating scale (NRS) every 4 hours
for 48 hours. The results elicited a reduction is dynamic pain in group 1 (NRS score: 2.7,
95% CI: 2.2-3.1 vs 6.8, 6.4-7.2; p< 0.0001). They also noted there was no morphine
consumption or significant pain at rest at any given time. Of note, seven patients from
the control group were treated for nausea compared to only one from group 1 (Kardash et
al., 2008). The researchers also measured an anti-inflammatory marker, C-reactive
protein, in a subgroup of 25 patients 48 hours postoperatively. They concluded patients
who received dexamethasone had markedly reduced levels of C-reactive protein (52.4
mg/mL, 28.2-76.6 vs 194.2, 168.9-219.4; p < 0.0001) (Kardash et al., 2008).
As the above study notes, dexamethasone has been used as an anti-inflammatory.
Usage of dexamethasone has been shown to decrease prostaglandin production by
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inhibiting cyclooxygenase type II, phospholipase and other major cytokines including Creactive protein, tumor necrosis factor (TNF), and several interleukins (IL) (Nagelhout &
Plaus, 2014). In a study done by el Azab et al. (2002) nine out of seventeen patients
(group 1) undergoing cardiopulmonary bypass received dexamethasone 100mg before
anesthesia induction. The eight other patients were placed in the control group (group 2).
Perioperative plasma levels were measured for TNF, IL-4, IL-6, IL-8, and IL-10.
Postoperatively it was concluded that IL-8 and TNF did not significantly increase in
group 1 as compared to group 2 which had a greater increase than the preoperative values
(p < 0.05). Both groups had an increase in IL-6; However, group 1 had less of an
increase compared to group 2 (p < 0.05). Group 1 had a higher increase of IL-10
compared to group 2 (p < 0.05). Finally, group 2 had a decrease in IL-4, however it did
not change in group 1 (p < 0.05) (el Azab et al., 2002). Of note postoperatively, group 2
did have hyperthermia, tachycardia, increased pulmonary artery pressure, increased
respiratory rate, and a more prolonged stay in the intensive care unit. Despite the low
number of participants, the authors concluded from their study that postoperative
outcomes may improve from dexamethasone use prior to cardiac surgery due to the antiinflammatory effect on circulating cytokines (el Azab et al., 2002).
Steward et al. (2011) account that there have not been any adverse effects from a
single dose of dexamethasone. However, Nalgelhout & Plaus (2014), claim a transient
increase in blood glucose levels can be appreciated after the administration of
dexamethasone. However, a momentary increase in BG level for a diabetic may
negatively impact health outcomes. Patients with hyperglycemia during the surgical
period are at a greater risk for electrolyte imbalances, dehydration, increased risk of
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infection, fluid shifts, compromised wound healing, and ketoacidosis (Joshi et al., 2010).
Despite it’s proven anti-inflammatory effects and anti-pain properties, the use of
dexamethasone in the diabetic population has been controversial related to the degree of
BG fluctuation. This systematic review examines more recent studies to determine the
extent in which dexamethasone effects BS in the diabetic patient.
Next, the theoretical framework will be presented.
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Theoretical Framework
A guide for evaluating systematic reviews was identified by Moher et al. in 2009.
They articulated that a systematic review incorporates “a clearly formulated question that
uses systematic and explicit methods to identify, select, and critically appraise relevant
research, and to collect and analyze data from the studies that are included in the review”
(Moher et al., 2009, p. 264). This process is of utmost importance for health care
workers due to many policies, practices, and further research are guided by systematic
reviews. In order to guide this systematic review, the Preferred Reporting Items for
Systematic Reviews and Meta- Analyses (PRISMA) theoretical framework will be used.
The PRISMA theoretical framework has a 27-point checklist to guide the
researcher through critical appraisal of each RCT to be used. This ensures an analytical
and unbiased evaluation is made of each RCT. The checklist provides the researcher
with a step-by-step guide for examining the RCT, including their introduction, methods,
results, and discussion. Once the initial research has been conducted, PRISMA uses a
flow diagram to elicit the extent of the search. The four phases consist of identification,
screening, eligibility, and studies included. This allows the researcher to present the
extent of their search and screening process for their systematic review (Moher et al.,
2009).
In order to facilitate an unbiased, thoroughly conducted systematic review, the use
of PRISMA will be implemented when examining the use of dexamethasone in adult
diabetic surgical patients to prevent PONV and the impact on blood glucose levels.
Next, the methods will be presented.
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Methods
Purpose
The purpose of this study was to examine the use of dexamethasone and the
impact on blood glucose levels for the prevention of PONV in adult diabetic surgical
patients. In order to thoroughly examine this issue, a systematic review of multiple
randomized control trials was completed.
Inclusion/Exclusion Criteria
Inclusion criteria for the studies included: (a) adults 18 years of age and older, (b)
patients undergoing surgery, (c) the use of dexamethasone for PONV, (d) patients with
the diagnosis of diabetes mellitus type I or type II. Exclusion criteria for the studies
included: (a) pediatric patients, (b) gestational diabetic patients.
Search Strategy
A detailed search was performed using CINAHL (Cumulative Index to Nursing
and Allied Health Literature) and MEDLINE. Keywords utilized were: “dexamethasone”
AND “diabet*” AND “postoperative nausea and vomiting” OR “PONV”. Restrictions of
English language and human subjects were implemented to the search.
Data Collection
Data collected from each study included: study purpose, design, and location;
number of subjects included, type of surgery; baseline, intraoperative, and postoperative
blood glucose levels; along with dexamethasone dosage and the use of placebo and/or
other anti-emetic pharmacologic treatment.
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Critical Appraisal
Literature collected was critically appraised using Critical Appraisal Skills
Progamme (CASP). CASP (Table 3) combines a three-step approach and a checklist to
guide the researcher in ensuring validity when synthesizing research (Critical Appraisal
Skills Programme, 2017). After completion of each study evaluation and summary a
comprehensive cross study analysis was completed.
Table 3
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist.
A. Are the results of the trial valid?
Yes
Can’t tell
1. Did the trial address a clearly focused
issue?
2. Was the assignment of patients to
treatments randomized?
3. Were all of the patients who entered
the trial properly accounted for at its
conclusion?
4. Were patients, health workers, and
study personnel “blind” to treatment?
5. Were the groups similar at the start of
the trial?
6. Aside from the experimental
intervention, were the groups treated
equally?
B. What are the results?
Yes
Can’t tell
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
C. Will the results help locally?
Yes
Can’t tell
9. Can the results be applied in your
context?
10. Were all clinically important
outcomes considered?
11. Are the benefits worth the harms and
costs?
Note: CASP checklist completed on all studies that met inclusion criteria.

No

No

No

28
Data Synthesis & Cross Study Analysis
Upon completion of each individual study evaluation and summary a
comprehensive cross study analysis was completed. The cross-study analysis compared
dexamethasone dosing, use of placebo or other anti-emetic pharmacologic treatment, and
the evaluation of baseline, intraoperative, and postoperative blood glucose levels.
Next, the results will be presented.
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Results
Figure 1
Completed PRISMA flow diagram demonstrating article identification, screening,
eligibility, and inclusion (Moher et al., 2009).
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The completed PRISMA flow diagram as depicted in Figure 1 illustrates a visual
analysis of how the four final studies were gathered to complete this systematic review.
An initial search of the selected databases, CINAHL and MEDLINE, was completed
using the search term “dexamethasone”, resulting in 72,395 studies. The addition of
search term “diabet*” narrowed the results to 2,520 studies. By adding “postoperative
nausea and vomiting” OR “PONV” to the search field, the results were narrowed down to
35 studies. A total of seven articles were excluded due to duplication. After article
screening, 31 studies were excluded due to failing to meet previously identified inclusion
criteria. Lastly, the remaining four studies were appraised and chosen to complete this
systematic review to examine the use of dexamethasone and the impact on blood glucose
levels for the prevention of PONV in adult diabetic surgical patients.
Each of the four studies selected and appraised for this systematic review include
a description of the results with applicable study findings identified. Appendix A (Tables
A1 – A4) depicts study specific data that was collected for each individual study. Each
individual table includes the following key information: purpose of the study, study
design, location, sample make up, methods used, and surgical procedure performed.
Following is Appendix B (Tables B1 – B4) which lists the outcome data that was
collected. Study specific findings include: BG sample times, baseline BG reading, mean
peak BG levels and maximum BG levels. Each table does have a degree of
individualization due to variance in each study. Next, Appendix C (Tables C1 – C4) lists
the critical appraisal data tables of individual studies that were created to assess the
legitimacy, consistency, and applicability through a three-part, 11 question series.
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Finally, Appendix D, a cross-study analysis data table was created to assist in comparing
the results of each individual study.
Individual Studies
The single-center, prospective, double-blind randomized trial by Nazar et al.
(2009) (Appendix A – 1) investigated the effect of administering dexamethasone in the
perioperative period on patients with poor glycemic control undergoing laparoscopic
Roux-en-Y gastric bypass surgery. A total of 30 obese patients (BMI >35kg/m2) with
impaired glucose tolerance were randomly divided into two groups. Group 1, the
dexamethasone group consisted of 15 participants while the remainder 15 participants
compromised group 2, the control group. Group 1 received dexamethasone 8mg IV
immediately after induction of anesthesia, while Group 2 received 2ml of isotonic saline
IV at the same designated time. Standardized surgical technique, per institution protocol,
was followed and the participants received a total gastroplasty with gastric pouch (30ml)
with 150 cm exclusion of small intestine and gastrojejunal anastomosis. Baseline BG
level was obtained preoperatively with IV placement. BG levels were reassessed every
two hours after surgical start for 12 hours. A difference of 45 mg/dl in peak glucose
values between groups was considered statistically significant. The BG levels were not
corrected during the study.
Outcomes of this study by Nazar et al. (2009) (Appendix B – 1) concluded that all
BG samples measured after the beginning of surgery were higher compared to baseline in
both groups. Group 1, the dexamethasone group, exhibited higher BG levels from the 6th
to the 12th hour after anesthesia compared to the control group. Group 2 maximum BG
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levels were found to be significantly different compared to Group 1 (Group 1: M = 187.2
versus Group 2: M = 158.4) (p-value <0.05) (Nazar et al., 2009).
When assessing the integrity of the study using the CASP questionnaire
(Appendix C, Table C – 1), the trial addressed a clearly focused issue in which all of the
participants were randomized to treatment and it was also noted that study personnel,
participants, healthcare workers were “blind” to treatment. Both groups were similar at
the start of the trial, treated equally aside from the experimental intervention, and all of
the participants were accounted for at the end of the trial. The results can be applied to
diabetics undergoing surgical procedures however the study is limited due to the small
number of participants (Nazar et al., 2009). Due to a hyperglycemia having an impact on
wound healing and infection rates, this study did not examine all clinically important
outcomes (Guvener et al., 2002). As a result, it is inconclusive whether the benefits
outweigh the risks.
This single -center, placebo-controlled study by Abdelmalak et al. (2013) was
randomized to dexamethasone or placebo and stratified by the presence or absence of
diabetes (Appendix A, Table A-2). The patients were part of a larger underlying study in
which they were randomized to either tight glucose control with a target plasma
concentration of 80 to 110 mg/dl or conventional glucose control of 180 to 200 mg/dl,
regardless of diabetic status: The Dexamethasone, Light Anesthesia and Tight Glucose
Control [DeLiT] Trial (Abdelmalak et al., 2013). This study’s purpose was to investigate
the change of blood glucose, from preoperative to maximal intraoperative, after
administration of dexamethasone 8mg IV to diabetic and nondiabetic patients undergoing
noncardiac surgery under general anesthesia. A total of 185 patients ≥ 40 years of age,
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restricted to the conventional glucose group, were divided into four groups. Group 1
consisted of 21 diabetic patients who received dexamethasone 8mg IV 1-2 hours prior to
incision, Group 2 comprised of 28 diabetic patients who received a placebo, Group 3
consisted of 69 nondiabetic patients who received dexamethasone 8mg IV 1-2 hours prior
to incision, and Group 4 comprised 67 nondiabetic patients who received a placebo.
Fasting BG levels were obtained preoperatively. A mean group difference of ≥ 28 mg/dl
signified clinical relevance. Insulin was given when BG levels were >215 mg/dl to
maintain target range of 180 to 200 mg/dl. Baseline BG was assessed preoperatively and
then reassessed at least hourly when stable and every 30 minutes after intervention.
Stable BG was defined by Abdelmalak et al. (2013) as a BG < 215 which required no
intervention such as insulin bolus or adjustment of insulin infusion, with two
consecutively similar BG readings. Interventions included insulin boluses or adjustment
of insulin infusion rate. All patients received a general anesthetic with sevoflurane in air
and oxygen for a noncardiac surgery in addition to a standardized infusion of IV fentanyl
(Abdelmalak et al., 2013).
Outcomes of this study by Abdelmalak et al. (2013) (Appendix B, Tables B – 2.12) demonstrated the mean maximal BG change did not change significantly between the
diabetic and nondiabetic patients (p=0.39). Dexamethasone increased the mean maximal
BG change compared to control in nondiabetic patients (Group ND1: M = 86mg/dl,
versus Group ND2: M = 58mg/dl) (p=0.0012). However, there wasn’t a hyperglycemic
response to dexamethasone observed in diabetic patients (Group DM1: M = 63mg/dl
versus Group DM2: M = 63mg/dl), (p=0.99) (Abdelmalak et al., 2013).
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When assessing the integrity of the study using the CASP questionnaire
(Appendix C, Table C – 2), the trial addressed a clearly focused issue in which all of the
participants were randomized to treatment and it was also noted that study personnel,
participants, healthcare workers were “blind” to treatment. The groups were not similar
at the start of the trial, diabetic patients were outnumbered 49 compared to 136. Also,
interventions were implemented aside from the experimental intervention for patients
with BG >215mg/dl. All of the participants were accounted for at the end of the trial.
The results can be applied to patients undergoing surgical procedures however the study
is limited due to treatment received when BG >215mg/dl (Abdelmalak et al., 2013). Due
to a hyperglycemia having an impact on wound healing and infection rates, this study did
not examine all clinically important outcomes (Guvener et al., 2002). As a result, it is
inconclusive whether the benefits outweigh the risks.
The single-center, prospective, randomized trial by Tien et al. (2016) (Appendix
A, Table A – 3) investigated the effect of prophylactic administration of dexamethasone
or ondansetron for prevention of postoperative nausea and vomiting and the effects on
blood glucose levels in non-diabetic and type-2 diabetic surgical patients. A total of 85
adult English-speaking patients scheduled for a general anesthetic elective surgery
anticipated to last >1 hour and expected to be admitted to the hospital for at least 24
hours were divided into 4 groups. Group 1 consisted of 20 non-diabetic participants who
received dexamethasone 8mg IV at induction of anesthesia, Group 2 comprised 21 nondiabetic participants who received 4mg ondansetron IV towards the end of the procedure,
Group 3 consisted of 20 type 2 diabetic patients who received dexamethasone 8mg IV at
induction of anesthesia, and Group 4 comprised 24 type 2 diabetic patients who received
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ondansetron 4mg IV towards the end of the procedure. Baseline BG was obtained
preoperatively and sent to the central laboratory for measurement. A mean increase in BG
levels by 30.6 mg/dl was to be considered significant. Additional BG samples were sent
at set time intervals: 2 hours, 4 hours, and 24 hours. A variety of surgical procedures
were preformed and classified into the following groups: open gynaecological,
laparoscopic gynaecological, open abdominal, laparoscopic abdominal, or other (Tien et
al., 2016).
Outcomes of this study by Tien et al. (2016) (Appendix B, Table B – 3)
demonstrated in non-diabetic patients, the maximum BG was higher in those who
received dexamethasone compared to those who received ondansetron (p = 0.04); the
same conclusion was exhibited with type 2 diabetic patients who received dexamethasone
compared to those who received ondansetron (p < 0.01).
When assessing the integrity of the study using the CASP questionnaire
(Appendix C, Table C – 3), the trial addressed a clearly focused issue in which all of the
participants were randomized to treatment and it was also noted that study personnel,
participants, healthcare workers were “blind” to treatment. The groups were not similar
at the start of the trial, patients selected for the study were diabetic and non-diabetic, of
varying age, and received various types of surgery. Also, an intervention of
subcutaneous insulin was implemented aside from the experimental intervention for
diabetic patients whose BG levels > 200 mg/dl. All of the participants were not
accounted for at the end of the trial, three out of 88 patients were discharged early from
the hospital and considered lost to follow-up. The results can be applied to patients
undergoing surgical procedures however the study is limited due to treatment received
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when BG >200mg/dl (Tien et al., 2016). Due to a hyperglycemia having an impact on
wound healing and infection rates, this study did not examine all clinically important
outcomes (Guvener et al., 2002). As a result, it is inconclusive whether the benefits
outweigh the risks.
The final study included in this systematic review is a single-center, prospective,
placebo-controlled randomized trial by Purushothaman et al. (2018) (Appendix A, Table
A – 4) investigated the effect of administering two low doses (4mg or 8mg) of
dexamethasone on BG levels of diabetic and nondiabetic patients receiving spinal
anesthesia for elective surgeries. A total of 180 elective surgical patients aged 18 – 70
years undergoing spinal anesthesia were divided into six groups: group 1, the diabetic
control group consisted of 30 patients; group 2, consisted of 30 diabetics who received
dexamethasone 4mg IV immediately prior to delivery of spinal anesthetic; group 3,
consisted of 30 diabetics who received dexamethasone 8mg IV immediately prior to
delivery of spinal anesthetic; group 4, the nondiabetic control group consisted of 30
patients; group 5, consisted of 30 nondiabetics who received dexamethasone 4mg IV
immediately prior to delivery of spinal anesthetic; and group 6, consisted of 30
nondiabetics who received dexamethasone 8mg IV immediately prior to delivery of
spinal anesthetic. Baseline capillary BG level was obtained immediately prior to
administration of dexamethasone or control and reassessed every hour for 7 hours. A
mean BG change of 23 mg/dl was to be considered clinically significant. The test drugs
were reconstituted to a volume of 5mls and given immediately prior to delivery of spinal
anesthetic. A standardized spinal anesthetic was followed using aseptic technique – a 25gauge Quincke needle was used to deliver 0.5% hyperbaric bupivacaine 15mg and
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buprenorphine 60 mcg at either L2-L3 or L3-L4 midline approach. A total of 133 general
surgeries, 24 gynecologic, and 43 orthopedic/plastic and other surgeries were included
(Purushothaman et al., 2018).
Outcomes of this study by Purushothaman et al. (2018) (Appendix B, Table B –
4.1-2) demonstrated that there was a rise in BG levels in both diabetic and nondiabetic
groups who received dexamethasone. However, this rise was not clinically significant
with a range of 10-15 mg/dl from baseline. Blood glucose levels peaked at 240 minutes
in group 2, the diabetic group that received 4mg dexamethasone IV, which was a
statistically significant increase from baseline. Blood glucose levels in the group 3, the
diabetic group that received 8mg dexamethasone IV peaked at 300 minutes. Blood
glucose levels peaked in the group 5, the nondiabetic group that received dexamethasone
4mg IV, and group 6, the nondiabetic group that received dexamethasone 8mg IV, at 300
minutes and 360 minutes, respectively. At 480 minutes, in comparison with the group 3,
group 6 had a statistically significant increase in BG levels (Purushothaman et al., 2018).
When assessing the integrity of the study using the CASP questionnaire
(Appendix C, Table C – 4), the trial addressed a clearly focused issue in which all of the
participants were randomized to treatment and it was also noted that study personnel,
participants, healthcare workers were “blind” to treatment. The groups were not similar
at the start of the trial due to a variety of surgical procedures being performed. However,
the groups were treated equally aside from the experimental intervention, and all of the
participants were accounted for at the end of the trial. The results can be applied to
diabetics undergoing surgical procedures however the study is limited due to the
participants received a spinal anesthetic which is different compared to all of the other
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studies who received a general anesthetic (Purushothaman et al., 2018). Due to a
hyperglycemia having an impact on wound healing and infection rates, this study did not
examine all clinically important outcomes (Guvener et al., 2002). As a result, it is
inconclusive whether the benefits outweigh the risks.
Cross-Study Analysis
The cross-study analysis table (Appendix D) exhibits the PONV prophylaxis used
for each study, as well as the major outcomes investigated including: Mean BG at 2
hours, 4 hours, 6 hours, and 8 hours; as well as mean peak BG levels. Each study had a
varying time frame in which BG samples were measured. Nazar et al. (2009) measured
mean BG at all of the above time frames mentioned. Abdelmalak et al. (2013) did not list
any BG levels for their four groups, instead listed overall mean peak BG levels. Tien et
al. (2016) listed mean BG for 2 hours, 4 hours and mean peak BG. Purushothaman et al.
(2018) listed all of the mean BG at all of the above time frames mentioned.
All studies included dosing of dexamethasone 8mg IV in diabetic patients and
was compared against a diabetic control (study 1, 2, and 4), a nondiabetic control (study 2
and 4), nondiabetic patients receiving dexamethasone 8mg IV (study 2 and 4),
nondiabetic and diabetic patients receiving ondansetron 4mg IV (study 3) and
nondiabetic and diabetic patients receiving dexamethasone 4mg IV (study 4). There was
an increase in mean peak BG in diabetic patients receiving dexamethasone 8mg IV
compared to diabetic control in study 1 and 4, however it was only clinically significant
in study 1 (p<0.05). In study 2 there was not a change in mean peak BG in the diabetic
patients receiving dexamethasone 8mg IV compared to the diabetic control group (Group
DM1: M = 209mg/dl versus Group DM2: M = 209mg/dl). There was an increase in
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mean peak BG in diabetic patients receiving dexamethasone 8mg IV compared to the
nondiabetic control group in study 2 (Group DM1: M = 209mg/dl versus Group ND2: M
= 154mg/dl) and study 4 (Group DM3: M = 168mg/dl versus Group ND4: M =
105mg/dl). In the diabetic groups receiving dexamethasone 8mg IV, there was a small
increase in BG compared to nondiabetic patients receiving dexamethasone 8mg IV in
study 2 (Group DM1: M = 209mg/dl versus Group ND1: M = 182mg/dl) and study 4
(Group DM3: M = 168mg/dl versus Group ND6: M = 140mg/dl). In study 3, the diabetic
group receiving dexamethasone 8mg IV had an overall increase in mean peak BG
compared to the diabetic group receiving ondansetron (Group DM3: M = 252mg/dl
versus DM4: M = 192.6 mg/dl). There was also an increase in BG in the diabetic group
receiving dexamethasone 8mg IV compared to both nondiabetic groups receiving either
dexamethasone or ondansetron, respectively (Group DM3: M = 252mg/dl versus Group
ND1: M = 163.8mg/dl versus Group ND2: M = 140.4mg/dl). In study 4, the diabetic
group receiving dexamethasone 8mg IV had an increase in mean peak BG compared to
the nondiabetic group that received dexamethasone 4mg IV (Group DM3: M = 168mg/dl
versus Group ND5: M = 133mg/dl). However, when the diabetic group receiving
dexamethasone 8mg IV is compared to the diabetic group receiving dexamethasone 4mg
IV, the latter group has a higher BG (Group DM3: M = 168mg/dl versus Group DM2: M
= 169mg/dl).
Next, the summary and conclusions will be presented.
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Summary and Conclusions
In the United States, DM is the sixth most common cause of death, with severe
implications on other leading causes of mortality: cardiovascular and cerebrovascular
disease (Coursin et al., 2004). The incidence of type 2 DM far outweighs type 1 with 810% of all Americans or 95% of all diabetics having type 2. This number is projected to
double in the United States within the next several decades, affecting a third to a quarter
of the population (Coursin et al., 2004). This has significant implications for the health
care system when there is an 18 – 22 year loss of estimated quality adjusted life years for
patients with a diagnosis of diabetes. Along with a loss of years lived, diabetics undergo
an increased amount of surgeries and procedures, necessitate more hospitalizations,
longer lengths of stay, and at greater cost compared to nondiabetic patients (Coursin et
al., 2004). As an independent risk factor for poor outcomes, hyperglycemia in the
perioperative period becomes a major concern for the anesthetist. Many type 2 diabetics
fail to be diagnosed until the time of their procedure or illness, with as many as 50% of
patients developing significant end organ compromise prior to diagnosis. The majority of
diabetic patients over the age of 65 have significant asymptomatic or symptomatic
coronary artery disease, in which the development of autonomic neuropathy increases the
incidence of silent ischemia (Coursin et al., 2004). Diabetics with autonomic neuropathy
have an increased risk of PONV and aspiration related to delayed gastric emptying.
Aspiration is the leading cause of mortality in anesthesia prompting serious consideration
and planning during the perioperative period (Robinson & Davidson, 2014).
Independently, PONV is the second most common complaint occurring in 20 to
40% of all surgical patients (Cao et al., 2017). The occurrence of PONV can prolong
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recovery, delay discharge, and result in unanticipated hospital admission (Shaikh et al.,
2016). Diabetic patients already have increased rates of hospitalizations and
complications; coupled with autonomic neuropathy contributing to PONV, a strategic
plan must be implemented to provide the safest anesthetic.
One of the most extensively used anti-emetics in the perioperative period is
dexamethasone, a glucocorticoid. The use of dexamethasone has been associated with
potential risks including impaired wound healing, increased blood glucose levels, and an
increase risk of infection (Miller et al., 2015). These risk factors, combined with
independent risk factors related to diabetes, make its use in the diabetic population
controversial.
The purpose of this systematic review was to examine the impact of
dexamethasone on blood glucose levels in the adult diabetic surgical patient when used in
the prevention of PONV. A comprehensive literature review was completed using
PubMed, Medline, CINAHL, and google scholar focusing on the pathology of diabetes
and postoperative nausea and vomiting, and the pharmacology of dexamethasone. The
theoretical framework used for this systematic review was PRISMA, a four-phase
flowchart compromised of 27-item checklist. This checklist ensured an analytical and
unbiased evaluation was made of each RCT (Moher et al., 2009).
Upon narrowing down the search results, individual study analysis was conducted
on four studies that met the inclusion criteria. Key information from each study was
incorporated into individualized study data tables. Data outcome tables were then
developed to analyze the effect of dexamethasone on perioperative blood glucose of
diabetic surgical patients. Following, the Critical Appraisal Skills Programme (CASP)
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checklist was used to appraise the individual RCTs. Finally, a cross study analysis table
was developed comparing the mean BG at 2 hours, 4 hours, 6 hours, 8 hours, and mean
peak BG levels. Diabetic patients receiving dexamethasone 8mg IV were compared to a
diabetic control; a nondiabetic control; nondiabetic patients receiving dexamethasone
8mg IV; nondiabetic and diabetic patients receiving ondansetron 4mg IV; and
nondiabetic and diabetic patients receiving dexamethasone 4mg IV.
There were several limitations recognized when completing this systematic
review. Each study had a diabetic group that received dexamethasone 8mg IV which was
used for comparison, however, the remaining groups all varied amongst the individual
studies. Three out of four studies had diabetic control groups with two of those studies
also including nondiabetic control groups. One study failed to have a control group,
comparing BG levels with diabetic and nondiabetic patients who received a different
antiemetic, ondansetron 4mg IV. Only one of the studies was performed on patients who
received the same surgical procedure, a laparoscopic Roux-en-Y gastric bypass. Two of
the other studies had varying surgical procedures under general anesthesia. The final
study was conducted under regional anesthesia. All of the studies performed a standard
preoperative BG assessment; however, the remaining intervals of assessment vary widely
from study to study. Another limitation for comparison is related to every study having a
different value for what BG change is considered to be significant, ranging from 23mg/dl
to 45mg/dl. One study in particular had limited findings due to the use of insulin for any
BG > 215mg/dl. Also, one study infused a glucose (5%) and electrolyte infusion to all
patients at a rate of 80ml/hr. Lastly, none of the studies examined the incidence of
complications related to hyperglycemia.

43
The findings of this systematic review determined that in the adult diabetic
surgical population, dexamethasone 8mg IV was associated with an increase in
perioperative BG levels. Although, the increase may not have been statistically
significant.
Next, the recommendations and implications for advanced nursing practice will
be presented.
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Recommendations and Implications for Advanced Nursing Practice
Diabetic surgical patients present with a variety of dynamic alterations in
physiologic response. Recognition and identification of patients with diabetes,
particularly those with impaired glucose tolerance and associated pathologies, becomes
imperative. This is especially important as over a third of diabetic patients are
undiagnosed, or untreated, when presenting for surgery (Vinik et al., 2003). Anticipation
of complications related to end-organ disease in the diabetic surgical patient is crucial for
the anesthesia provider when constructing the anesthetic plan. Perioperatively, diabetic
patients have a two- to threefold increase in morbidity and mortality related to
cardiovascular complications. Much of the organ dysfunction can be related to diabetic
autonomic neuropathy produced from diffuse damage to peripheral nerves and small
vessels. The widespread distribution of the autonomic nervous system (ANS) renders all
organs susceptible to dysfunction (Vinik et al., 2003).
Diabetic autonomic neuropathy first manifests in longer nerves. The Vagus nerve
is responsible for ~75% of all parasympathetic activity and is the longest nerve, resulting
in early dysfunction. Gastric emptying (gastroparesis) principally relies on vagal nerve
function. Approximately 50% of patients with chronic diabetes suffer from gastroparesis,
increasing their perioperative risk for nausea and vomiting and also aspiration.
Preoperative testing must be focused on identification and treating coexisting conditions
to ensure patients are optimized in order to reduce the incidence of perioperative
complications (Kadoi, 2010).
Due to increased gastric dysfunction, diabetic patients require careful
consideration when planning prophylaxis treatment of postoperative nausea and vomiting
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(PONV). Dexamethasone is one of the most common prophylactic medications used in
the perioperative period for its antiemetic and analgesic effects. The use of
dexamethasone is, however, also associated with impaired wound healing and
hyperglycemia, which are complications diabetic patients are already predisposed to
(Godshaw et al., 2019). A retrospective chart review completed by Godshaw et al.
(2019) examined the use of dexamethasone in prevention of PONV and for analgesia in
2,317 patients undergoing primary total hip or knee arthroplasty. The primary outcome
evaluated was the incidence of prosthetic joint infection (PJI). Participants were
principally divided into dexamethasone group and no dexamethasone group, and then
further subdivided into diabetic and nondiabetic cohorts. There were 428 diabetic
patients in the dexamethasone group that received either 6mg or 12mg of IV
dexamethasone preoperatively and 229 diabetics that were allocated in the no
dexamethasone group. A total of 25 (1.08%) PJIs were reported in the study, with
diabetics having a significantly higher incidence of PJI in comparison to nondiabetics
(2.59% versus 0.48%, p < 0.001). There was no significant interaction between the use
of dexamethasone and diabetic status (p = 0.646). This suggests that the use of
dexamethasone was not a contributory factor in the development of PJI (Godshaw et al.,
2019).
This systematic review concluded that dexamethasone was associated with an
increase in perioperative blood glucose levels, although a significant increase was not
found among all studies. The Society for Ambulatory Anesthesia suggests that for the
well-controlled diabetic patient, intraoperative BG levels should be maintained <180
mg/dL (10.0 mmol/L) and poorly controlled diabetics should be maintained around their
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preoperative baseline (Joshi et al., 2010). Chronic elevation of blood glucose levels in
the diabetic patient should not be treated perioperatively with insulin due to altered
counterregulatory responses leading to hypoglycemic symptoms at decreased and/or
“normal” levels (Joshi et al., 2010). Vigilance from the anesthesia provider is required in
monitoring intraoperative blood glucose levels due to the detrimental effects of both hypo
and hyperglycemia.
The management of the diabetic patient during the perioperative period must be
tailored to each individual patient. Hyperglycemia and hypoglycemia are associated with
increased morbidity and mortality; therefore, it is up to the anesthesia provider to monitor
the patient’s blood glucose levels throughout the perioperative period in order to deter
these complications (Joshi et al., 2010). Despite widely available point of care blood
glucose testing and the known incidence of hyperglycemia associated with
dexamethasone use; blood glucose levels may not be commonly monitored after
anesthesia. A retrospective study completed by Sudlow et al. (2017) examined the
incidence of subsequent measurement of blood glucose levels for 24-hours following
anesthesia. Out of 355 patients eligible for chart review, 243 (66%) received
dexamethasone at a median dose of 6.7mg. Only 16 patients (4.5%) received subsequent
blood glucose assessments. From these 16 patients, eight patients (50%) were diabetic
and only two patients received additional blood glucose assessments within the 24-hour
time period. Three patients with diabetes developed wound infections with noted blood
glucose levels ranging from 216 – 486 mg/dl within 24 hours postoperatively (Sudlow et
al., 2017).
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Individualization of the anesthetic plan is essential; the anesthesia provider must
assess and evaluate the patient to allow for anticipation of potential complications.
Although individualization is key, standardization of protocols, specifically, blood
glucose assessments during the perioperative period allow for safer management of the
diabetic patient. This study concluded that dexamethasone does increase blood glucose
levels after administration, therefore benefit versus harm must be weighed for each
patient. When choosing to use dexamethasone in the adult diabetic surgical population
for prevention of PONV, the risk of an increased stress response, possibility of impaired
wound healing, and increased risk of infection must be evaluated against the benefit of its
antiemetic and analgesic properties. Further research is needed to deduce whether a
single dose of dexamethasone for prevention of PONV has any correlation with adverse
outcomes such as surgical site infection or impaired wound healing. Communication
with the interdisciplinary teams caring for the patient is also important. A handoff report
to the PACU nurse, Advanced Practice Registered Nurse (APRN) and/or physician,
summarizing your anesthetic plan and possible future implications is necessary to
monitor for adverse outcomes. Continued education amongst providers and care givers is
necessary to promote the best possible outcomes while minimizing complications.
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Appendix A

Table A-1
Study Specific Data
Study 1: Nazar, C. E., Lacassie, H. J., López, R. A., & Muñoz, H. R. (2009). Dexamethasone for postoperative nausea and vomiting
prophylaxis: Effect on glycaemia in obese patients with impaired glucose tolerance. European Journal of Anaesthesiology, 26, 318-321.
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
Investigate the effect of
administering
dexamethasone in the
perioperative period on
patients with poor
glycemic control
undergoing laparoscopic
Roux-en-Y gastric
bypass surgery.

Single-center,
prospective,
double-blind
randomized trial.
Group 1 –
dexamethasone
Group 2 –
control group

Facultad de
Medicina,
Pontificia
Universidad
Católica de
Chile,
Santiago,
Chile.

30 obese patients
(BMI >35kg/m2)
with impaired
glucose tolerance
were randomly
divided into two
groups.
Group 1 – (n=15)
dexamethasone
Group 2 – (n=15)
control group
All patients
underwent
laparoscopic
Roux-en-Y
gastric bypass
surgery.

Baseline blood glucose (BG) level
was obtained in pre-op with IV
placement. BG levels reassessed
every 2 hours after surgical start for
12 hours. A difference of 2.5 mmol
liter-1 (45 mg/dl) in peak glucose
values between groups is considered
statistically significant. All patients
received a postoperative infusion of
glucose (5%) and electrolytes at a
rate of 80ml/hr. The BG levels were
not corrected during the study.
Group 1 –dexamethasone 8mg IV
immediately after induction of
anesthesia.
Group 2 – 2ml isotonic saline IV
immediately after induction of
anesthesia.

Standardized
surgical technique
per institution
protocol.
Total gastroplasty
with gastric pouch
(30ml) with 150cm
exclusion of small
intestine and
gastrojejunal
anastomosis.
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Appendix A

Table A-2
Study Specific Data
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden, S. P., & Sessler, D. I. (2013). The hyperglycemic
response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesthesia &
Analgesia, 115(5) 1116-1122
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
Investigate the change of
blood glucose from
preoperative to maximal
intraoperative after
administration of
dexamethasone 8mg IV
to diabetic and
nondiabetic patients
undergoing noncardiac
surgery under general
anesthesia.

Single-center, placebocontrolled,
randomized to dexamethasone
or placebo, stratified by the
presence or absence of
diabetes.
Group 1 – DM1 diabetics
receiving dexamethasone
Group 2 – DM2 diabetics
receiving placebo
Group 3 – ND1 nondiabetics
receiving dexamethasone
Group 4 – ND2 nondiabetics
receiving placebo

Cleveland
Clinic,
Cleveland,
Ohio, United
States of
America.

185 patients ≥40
years of age
undergoing major
noncardiac
surgery.
Restricted to all
patients in the
conventional
glucose group.
DM1 – (n=21)
diabetics receiving
dexamethasone
DM2 – (n=28)
diabetics receiving
placebo
ND1 –(n=69)
nondiabetics

Fasting BG level
was obtained
preoperatively. A
mean group
difference of ≥ 28
mg/dl signified
clinical relevance.
Insulin was given
when BG levels
were >215 mg/dl
to maintain target
range of 180 to 200
mg/dl
Sample 0:
preoperative; BG
was assessed at
least hourly when
stable* and every

All patients received a
general anesthetic
with sevoflurane in air
and oxygen for a
noncardiac surgery in
addition to a
standardized infusion
of IV fentanyl.
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Patients were part of a larger
underlying study in which
they were randomized to
either tight glucose control
with a target plasma
concentration of 80 to 110
mg/dl or conventional glucose
control of 180 to 200 mg/dl,
regardless of diabetic status:
The Dexamethasone, Light
Anesthesia and Tight Glucose
Control [DeLiT] Trial.

receiving
dexamethasone

30 minutes after
intervention**

ND2 –(n=67)
nondiabetics
receiving placebo

DM1 –
dexamethasone
8mg IV 1 to 2
hours pre-incision
DM2–placebo
ND1 –
dexamethasone
8mg IV 1 to 2
hours pre-incision
ND2 – placebo

Note: (*) Stable BG – no interventions such as insulin bolus or adjustment of insulin infusion, with two consecutively similar BG
readings. (**) Interventions included insulin boluses or adjustment of insulin infusion rate. DM – diabetic group, ND – nondiabetic
group.
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Appendix A

Table A-3
Study Specific Data
Study 3: Tien, M., Gan, T. J., Dhakal, I., White, W. D., Olufolabi, A. J., Fink, R., Mishriky, B. M., Lacassie, H. J., & Habib, A. S. (2016). The
effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: A prospective
randomized controlled study. Anaesthesia, 71, 1037-1043.
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHOD
PROCEDURE
Investigate the
effect of
prophylactic
administration of
dexamethasone or
ondansetron for
prevention of
postoperative
nausea and
vomiting and the
effects on blood
glucose levels in
non-diabetic and
type-2 diabetic
surgical patients.

Single-center,
prospective,
randomized trial.
Group 1 – nondiabetics receiving
dexamethasone
Group 2 – nondiabetics receiving
ondansetron
Group 3 –type 2
diabetics receiving
dexamethasone
Group 4 – type 2
diabetics receiving
ondansetron

Hospital perioperative unit,
United States

85 adult Englishspeaking patients
scheduled for a
general anesthetic
elective surgery
anticipated to last
>1 hour and
expected to be
admitted to the
hospital for at least
24 hours
Group 1 – (n=20)
non-diabetics
receiving
dexamethasone
Group 2 – (n=21)
non-diabetics

Baseline blood sample
was obtained in pre-op
and sent to the central
laboratory for
measurement. A mean
increase in BG levels by
1.7 mmol liter-1 (30.6
mg/dl) is to be
considered significant.
Additional samples
were sent at set time
intervals: 2 hours, 4
hours, and 24 hours.
Group 1 –
dexamethasone 8mg IV
at induction of
anesthesia.

A variety of surgical
procedures were
preformed and classified
into the following groups:
open gynaecological,
laparoscopic
gynaecological, open
abdominal, laparoscopic
abdominal, or other.
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receiving
ondansetron
Group 3 – (n= 20)
type 2 diabetics
receiving
dexamethasone
Group 4 – (n= 24)
type 2 diabetics
receiving
ondansetron

Group 2 – ondansetron
4mg IV towards end of
procedure
Group 3 –
dexamethasone 8mg IV
at induction of
anesthesia.
Group 4 – ondansetron
4mg IV towards end of
procedure
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Appendix A

Table A-4
Study Specific Data
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & Reddy, P. R. (2018). A prospective randomized study
on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi Journal of
Anesthesia, 12(2), 198-203.
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
Investigate the effect of
administering two low
doses (4mg or 8mg) of
dexamethasone on BG
levels of diabetic and
nondiabetic patients
receiving spinal
anesthesia for elective
surgeries

Single-center,
prospective,
placebocontrolled
randomized
trial.
Group 1
(DM0) –
diabetic
control group

Department of
Anaesthesiology,
Ramaiah Medical
College and
Hospital, Bengaluru,
Karnataka, India.

180 elective
surgical patients
undergoing spinal
anesthesia aged
18 – 70 years.
DM0 – (n=30)
diabetic control
group

Group 2
(DM4) –
diabetic group

DM4 – (n=30)
diabetic group
receiving
dexamethasone
4mg IV

Group 3
(DM8) –
diabetic group

DM8 – (n=30)
diabetic group
receiving

Baseline capillary BG level
was obtained immediately
prior to administration of
dexamethasone or control
and reassessed every hour
for 7 hours. A mean BG
change of 23 mg/dl is to be
considered clinically
significant. The test drugs
were reconstituted to a
volume of 5mls and given
immediately prior to
delivery of spinal anesthetic.
DM0 – 5ml normal saline
DM4 – dexamethasone 4mg
IV

A standardized spinal
anesthetic was followed
using aseptic technique 25-gauge Quincke needle
delivering 0.5%
hyperbaric bupivacaine
15mg and buprenorphine
60 mcg at either L2-L3 or
L3-L4 midline approach.
A total of 133 general
surgeries, 24 gynecologic,
and 43 orthopedic/plastic
and other surgeries were
included.
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Group 4
(ND0) –
nondiabetic
control group
Group 5
(ND4) –
nondiabetic
group
Group 6
(ND8) –
nondiabetic
group

Note: DM – diabetic group, ND – nondiabetic group

dexamethasone
8mg IV
ND0 – (n=30)
nondiabetic
control group

DM8 – dexamethasone 8mg
IV
ND0 – 5ml normal saline
ND4 – dexamethasone 4mg
IV

ND4 – (n=30)
ND8 – dexamethasone 8mg
nondiabetic group IV
receiving
dexamethasone
4mg IV
ND8 – (n=30)
nondiabetic group
receiving
dexamethasone
8mg IV
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Table B-1
Outcome Data Collection
Study 1: Nazar, C. E., Lacassie, H. J., López, R. A., & Muñoz, H. R. (2009). Dexamethasone for postoperative nausea and vomiting
prophylaxis: Effect on glycaemia in obese patients with impaired glucose tolerance. European Journal of Anaesthesiology, 26, 318-321.
Group 1
Group 2
Time after start of
dexamethasone
control
p-value
Significance
surgery (hours)
(n=15)
(n=15)
BG (mg/dl) •
BG (mg/dl) •
All BG samples measured
Baseline
90.0 ± 10.8
88.2 ± 9.0
after the beginning of
surgery were higher
2
*
122.4 ± 28.8
129.6 ± 32.4
compared to baseline in
both groups. Group 1, the
4
*
147.6 ± 25.2
135.0 ± 18.0
dexamethasone group,
6
*†
158.4 ± 18.0
126.0 ± 18.0
exhibited higher BG levels
from the 6th to the 12th hour
†
8
*
176.4 ± 25.2
129.6 ± 36.0
after anesthesia compared to
the control group.
10
*†
180.0 ± 32.4
127.8 ± 34.2
12
Maximum BG levels

162.0 ± 21.6

122.4 ± 28.8

*†

187.2 ± 28.8

158.4 ± 30.6

< 0.05

Note. (•) BG concentration converted to mg/dl with formula: mg/dl = 18 x mmol liter-1. (*) A p-value of less than 0.05 compared with
baseline with the paired Student’s t-test. (†) A p-value of less than 0.05 between the groups with the unpaired Student’s t-test.
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Table B-2.1
Outcome Data Collection
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden, S. P., & Sessler, D. I. (2013). The hyperglycemic
response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesthesia & Analgesia,
115(5) 1116-1122
Group DM1
Group DM2
dexamethasone 8mg IV
control
Mean Difference
BG sample times
p-valuea
Significance
(n= 21)
(n=28)
(97.5% CI)a
BG (mg/dl)
BG (mg/dl)
Mean maximal BG change
Diabetic baseline BG
143.0 ± 53.0
did not change significantly
between the DM and ND
patients (p=0.39).
Intraoperative maximal
0 (-33, 33)
0.99
63.0 ± 66.0
63.0 ± 72.0
Dexamethasone increased
BG change
the mean maximal BG,
Diabetic mean maximal
change compared to control,
0.39
63.0 ± 69
BG change
in ND patients (p=0.0012);
no hyperglycemic response
Diabetics given insulin
to dexamethasone was seen
19 of 49 (39%)
<0.001
treatment intraoperatively
in DM patients (p=0.99).

Note. DM – diabetic group, ND – nondiabetic group, CI – confidence interval. (a) Linear regression model incorporating factors for
placebo vs dexamethasone and DM vs ND; the interaction between DM and dexamethasone was significant (p= 0.094, less than
criterion of p< 0.10); Bonferroni correction was used for two comparisons (a = 0.05/2 = 0.025).
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Table B-2.2
Outcome Data Collection
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden, S. P., & Sessler, D. I. (2013). The hyperglycemic
response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesthesia &
Analgesia, 115(5) 1116-1122
Group ND1
Group ND2
BG sample
dexamethasone 8mg IV
control
Mean Difference
p-valuea
Significance
times
(n=69)
(n=67)
(97.5% CI)a
BG (mg/dl)
BG (mg/dl)
Nondiabetic
96.0 ± 19.0
baseline BG
Mean maximal BG change did not
Intraoperative
change significantly between the
maximal BG
29 (9, 49)
0.0012
86.0 ± 41.0
58.0 ± 45.0
DM and ND patients (p=0.39).
change
Dexamethasone increased the mean
Nondiabetic
maximal BG, change compared to
mean maximal
0.39
72.0 ± 54
control in ND patients (p=0.0012);
BG change
no hyperglycemic response to
dexamethasone was seen in DM
Nondiabetics
patients (p=0.99).
given insulin
8 of 136 (6%)
<0.001
treatment
intraoperatively

Note: DM – diabetic group, ND – nondiabetic group, CI – confidence interval. (a) Linear regression model incorporating factors for
placebo vs dexamethasone and DM vs ND; the interaction between DM and dexamethasone was significant (p= 0.094, less than
criterion of p< 0.10); Bonferroni correction was used for two comparisons (a = 0.05/2 = 0.025).

64

Appendix B
Table B-3
Outcome Data Collection
Study 3: Tien, M., Gan, T. J., Dhakal, I., White, W. D., Olufolabi, A. J., Fink, R., Mishriky, B. M., Lacassie, H. J., & Habib, A. S. (2016). The
effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: A prospective
randomized controlled study. Anaesthesia, 71, 1037-1043.
Group 1
non-diabetics
dexamethasone
(n=20)
BG (mg/dl) •

Group 2
non-diabetics
ondansetron
(n=21)
BG (mg/dl) •

p-value

Group 3
type 2 diabetics
dexamethasone
(n=20)
BG (mg/dl) •

Group 4
type 2 diabetics
ondansetron
(n=24)
BG (mg/dl) •

p-value

0h

95.4 ± 16.2

91.8 ± 14.4

0.62

124.2 ± 28.8

129.6 ± 34.2

0.59

2h

115.2 ± 18.0

118.8 ± 23.4

0.65

169.2 ± 50.4

145.8 ± 39.6

0.10

4h

153.0 ± 28.8

131.4 ± 28.8

0.02

187.2 ± 54.0

154.8 ± 37.8

0.08

24 h

126.0 ± 45.0

1170 ± 18.0

0.99

176.4 ± 45.0

149.4 ± 41.4

0.05

Mean Peak BG

163.8 ± 39.6

140.4 ± 25.2

0.04

252.0 ± 45.0

192.6 ± 43.2

<0.01

Maximum 4-h
BG change
Maximum 24-h
BG change
Maximum 24-h
BG >180

57.6 ± 30.6

41.4 ± 30.6

0.10

66.6 ± 48.6

28.8 ± 37.8

<0.01

68.4 ± 43.2

48.6 ± 30.6

0.09

126.0 ± 37.8

63.0 ± 39.6

<0.01

2 (10%)

0.13

19 (95%)

12 (50%)

<0.01

BG sample
times (hours)

6 (30%)

Note. (•) BG concentration converted to mg/dl with formula: mg/dl = 18 x mmol liter-1.

Significance

In non-diabetic
patients, the maximum
BG was higher in those
who received
dexamethasone
compared to those who
received ondansetron (p
= 0.04); the same
conclusion was
exhibited with type 2
diabetic patients who
received
dexamethasone
compared to those who
received ondansetron (p
< 0.01)
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Table B-4.1
Outcome Data Collection
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & Reddy, P. R. (2018). A prospective randomized study
on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi Journal of
Anesthesia, 12(2), 198-203.
Group 1 –
Group 2 – DM4
Group 3 – DM8
BG sample
DM0(n=30)
(n=30)
(n=30)
p-value
Significance
times
BG (mg/dl)
BG (mg/dl)
BG (mg/dl)
There was a rise in BG levels in both
T0
0.219
134.4 ± 22.8
125.6 ± 21.0
125.8 ± 22.6
diabetic and nondiabetic groups who
received dexamethasone. However,
T1
0.835
139.3 ± 24.5
137.7 ± 20.0
135.6 ± 26.1
this rise was not clinically significant
with a range of 10-15 mg/dl from
T2
0.426
141.2 ± 25.4
149.3 ± 20.6
143.3 ± 28.0
baseline. BG levels peaked at T4 in
T3
0.006*,†,‡
138.5 ± 26.0
161.3 ± 20.5
154.2 ± 34.2
the DM4 group, which was a
statistically significant increase from
T4
<0.001*,†,‡
147.3 ± 23.6
169.3 ± 21.8
166.8 ± 25.9
baseline. BG levels in the DM8 group
peaked at T5.
*,†,‡
T5
<0.001
144.4 ± 22.9
165.0 ± 21.4
167.5 ± 18.6
T6

146.9 ± 20.8

158.0 ± 25.4

160.2 ± 16.0

<0.037*,†,‡

T8

144.5 ± 20.6

151.2 ± 20.8

149.1 ± 17.0

0.401

Mean Peak BG

148.0 ± 17.2

169.0 ± 17.3

168.0 ± 22.4

Note. (*) Indicates p-value < 0.05 significant between the three groups by analysis of variance. Post hoc analysis between the groups
was done. (†) Indicates p-value < 0.05 significant between DM0 and DM4. (‡) Indicates p-value < 0.05 significant between DM0 and
DM8. T0 (baseline), T1 (60), T2 (120), T3 (180), T4 (240), T5 (300), T6 (360), and T8 (480) minutes after test drug administration.
DM: Diabetes group. DM0: control group, DM4: 4mg dexamethasone IV, DM8: 8mg dexamethasone IV.
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Table B-4.2
Outcome Data Collection
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., & Reddy, P. R. (2018). A prospective randomized study
on the impact of low-dose dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics. Saudi Journal of
Anesthesia, 12(2), 198-203.
BG sample
times

Group 4 – ND0
(n=30)
BG Concentration
(md/dl)

Group 5 – ND4
(n=30)
BG
Concentration
(mg/dl)

Group 6 – ND8
(n=30)
BG
Concentration
(mg/dl)

p-value

Significance

T0

96.3 ± 11.3

93.3 ± 11.6

95.5 ± 15.5

0.654

T1

99.7 ± 12.3

98.4 ± 14.8

98.5 ± 13.8

0.918

T2

102.1 ± 13.4

104.9 ± 18.9

104.8 ± 15.3

0.739

T3

104.9 ± 15.1

114.9 ± 19.3

116.9 ± 21.2

0.034*,‡

T4

100.9 ± 23.7

126.6 ± 23.3

129.4 ± 25.3

<0.001*,†,‡

T5

103.1 ± 24.5

133.1 ± 26.1

137.8 ± 23.8

<0.001*,†,‡

There was a rise in BG levels in both
diabetic and nondiabetic groups who
received dexamethasone. However, this rise
was not clinically significant with a range of
10-15 mg/dl from baseline. BG levels
peaked in the ND4 and ND8 groups at T5
and T6, respectively. At T8, in comparison
with the DM8 group, the ND8 group had a
statistically significant increase in BG levels.

T6

103.7 ± 15.3

124.3 ± 24.5

139.9 ± 27.9

<0.001*,†,‡,§

T8

100.3 ± 15.0

114.6 ± 21.3

131.1 ± 28.1

<0.001*,†,‡,§

105.0 ± 23.6
133.0 ± 20.4
140.0 ± 23.2
Note. (*) Indicates p-value < 0.05 significant between the three groups by analysis of variance. Post hocanalysis between the groups was done. (†)
Indicates p-value < 0.05 significant between ND0 and ND4. (‡) Indicated p-value < 0.05 significant between ND0 and ND8. (§) Indicates p-value <
0.05 significant between ND4 and ND8. T0 (baseline), T1 (60), T2 (120), T3 (180), T4 (240), T5 (300), T6 (360), and T8 (480) minutes after test
drug administration. ND: Nondiabetic group. ND0: control group, ND4: 4mg dexamethasone IV, ND8: 8mg dexamethasone IV.
Mean Peak BG
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Table C-1
Study 1: Nazar, C. E., Lacassie, H. J., López, R. A., & Muñoz, H. R. (2009). Dexamethasone
for postoperative nausea and vomiting prophylaxis: Effect on glycaemia in obese patients with
impaired glucose tolerance. European Journal of Anaesthesiology, 26, 318-321.
A)
Are the results of the trial valid?
Yes
Can’t tell
No
1.
Did the trial address a clearly focused
X
issue?
2.
Was the assignment of patients to
X
treatments randomized?
3.
Were all of the patients who entered the
X
trial properly accounted for at its conclusion?
4.
Were patients, health workers, and study
X
personnel “bind” to treatment?
5.
Were the groups similar at the start of the
X
trial?
6.
Aside from the experimental intervention,
X
were the groups treated equally?
B)
What are the results?
7.
How large was the treatment effect?
All BG samples measured after the
beginning of surgery were higher
compared to baseline in both groups.
8.
How precise was the estimate of the
Group 1, the dexamethasone group,
treatment effect?
exhibited higher BG levels from the 6th to
the 12th hour after anesthesia compared to
the control group.
C)
Will the results help locally?
Yes
Can’t tell
No
9.
Can the results be applied in your context?
X
10.
Were all clinically important outcomes
X*
considered?
11.
Are the benefits worth the harms and
X*
costs?

Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Note. (*) The study did not examine differences or complications in outcomes between
the two groups related to hyperglycemia, unable to determine.
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Table C-2
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 2: Abdelmalak, B. B., Bonilla, A. M., Yang, D., Chowdary, H. T., Gottlieb, A., Lyden,
S. P., & Sessler, D. I. (2013). The hyperglycemic response to major noncardiac surgery and the
added effect of steroid administration in patients with and without diabetes. Anesthesia &
Analgesia, 115(5) 1116-1122
A)
Are the results of the trial valid?
Yes
Can’t tell
No
1.
Did the trial address a clearly focused
X
issue?
2.
Was the assignment of patients to
X
treatments randomized?
3.
Were all of the patients who entered the
X
trial properly accounted for at its conclusion?
4.
Were patients, health workers, and study
X
personnel “bind” to treatment?
5.
Were the groups similar at the start of the
X†
trial?
6.
Aside from the experimental intervention,
X‡
were the groups treated equally?
B)
What are the results?
7.
How large was the treatment effect?
Mean maximal BG change did not change
significantly between the DM and ND
patients (p=0.39).
8.
How precise was the estimate of the
Dexamethasone increased the mean
treatment effect?
maximal BG, change compared to
control, in ND patients (p=0.0012); no
hyperglycemic response to
dexamethasone was seen in DM patients
(p=0.99).
C)
Will the results help locally?
Yes
Can’t tell
No
9.
Can the results be applied in your
X
context?
10.
Were all clinically important outcomes
X*
considered?
11.
Are the benefits worth the harms and
X*
costs?

Note. (†) Patients selected for the study were diabetic and non-diabetic, of varying
age, and received various types of surgery. (‡) Patients received insulin for BG levels >
215 mg/dl to maintain BG in the target range 180 to 200 mg/dl (*) The study did not
examine differences or complications in outcomes between the two groups related to
hyperglycemia, unable to determine.
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Table C-3
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 3: Tien, M., Gan, T. J., Dhakal, I., White, W. D., Olufolabi, A. J., Fink, R., Mishriky, B.
M., Lacassie, H. J., & Habib, A. S. (2016). The effect of anti-emetic doses of dexamethasone
on postoperative blood glucose levels in non-diabetic and diabetic patients: A prospective
randomized controlled study. Anaesthesia, 71, 1037-1043.
A)
Are the results of the trial valid?
Yes
Can’t tell
No
1.
Did the trial address a clearly focused
X
issue?
2.
Was the assignment of patients to
X
treatments randomized?
3.
Were all of the patients who entered the
X†
trial properly accounted for at its conclusion?
4.
Were patients, health workers, and study
X
personnel “bind” to treatment?
5.
Were the groups similar at the start of the
X‡
trial?
6.
Aside from the experimental
X††
intervention, were the groups treated equally?
B)
What are the results?
7.
How large was the treatment effect?
Multiple variate analysis illustrated that
use of dexamethasone was a significant
predictor of maximum postoperative BG
increase (p < 0.01).
8.
How precise was the estimate of the
In non-diabetic patients, the maximum BG
treatment effect?
was higher in those who received
dexamethasone compared to those who
received ondansetron (p = 0.04); the same
conclusion was exhibited with type 2
diabetic patients who received
dexamethasone compared to those who
received ondansetron (p < 0.01).
C)
Will the results help locally?
Yes
Can’t tell
No
9.
Can the results be applied in your
X
context?
10.
Were all clinically important outcomes
X*
considered?
11.
Are the benefits worth the harms and
X*
costs?

Note. (†) Three out of 88 patients were discharged early from the hospital and considered
lost to follow-up. (‡) Patients selected for the study were diabetic and non-diabetic, of
varying age, and received various types of surgery. (††) Diabetic patients received insulin
subcutaneously for BG levels > 200 mg/dl. (*) The study did not examine differences or
complications in outcomes between the two groups related to hyperglycemia, unable to
determine.
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Table C-4
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 4: Purushothaman, A. M., Pujari, V. S., Kadirehally, N. B., Bevinaguddaiah, Y., &
Reddy, P. R. (2018). A prospective randomized study on the impact of low-dose
dexamethasone on perioperative blood glucose concentrations in diabetics and nondiabetics.
Saudi Journal of Anesthesia, 12(2), 198-203.
A)
Are the results of the trial valid?
Yes
Can’t tell
No
1.
Did the trial address a clearly focused
X
issue?
2.
Was the assignment of patients to
X
treatments randomized?
3.
Were all of the patients who entered the
X
trial properly accounted for at its conclusion?
4.
Were patients, health workers, and study
X
personnel “bind” to treatment?
5.
Were the groups similar at the start of the
X‡
trial?
6.
Aside from the experimental intervention,
X
were the groups treated equally?
B)
What are the results?
7.
How large was the treatment effect?
There was a rise in BG levels in both
diabetic and nondiabetic groups who
received dexamethasone. However, this
rise was not clinically significant with a
range of 10-15 mg/dl from baseline.
8.
How precise was the estimate of the
BG levels peaked at T4 in the DM4 group,
treatment effect?
which was a statistically significant
increase from baseline. BG levels in the
DM8 group peaked at T5. BG levels
peaked in the ND4 and ND8 groups at T5
and T6, respectively. At T8, in
comparison with the DM8 group, the ND8
group had a statistically significant
increase in BG levels.
C)
Will the results help locally?
Yes
Can’t tell
No
9.
Can the results be applied in your
X
context?
10.
Were all clinically important outcomes
X*
considered?
11.
Are the benefits worth the harms and
X*
costs?

Note: (‡) Patients selected for the study were diabetic and non-diabetic, of varying age,
and received various types of surgery. (*) The study did not examine differences or
complications in outcomes between the two groups related to hyperglycemia, unable to
determine.
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Cross Study Analysis
Author, Year

Methods

Study 1
(Nazar et al.,
2009)

All BG samples measured
Group 1after the beginning of surgery
dexamethasone were higher compared to
8mg IV
baseline in both groups.
Group 1 exhibited higher BG
levels from the 6th to the 12th
Group 2hour after anesthesia
control
compared to the control
group.
Mean maximal BG change
Group 1-DM1 did not change significantly
dexamethasone between the DM and ND
8mg IV
patients (p=0.39).
Dexamethasone increased the
mean maximal BG, change
Group 2-DM2 compared to control in ND
control
patients (p=0.0012); no
hyperglycemic response to
dexamethasone was seen in
Group 3- ND1 DM patients (p=0.99).
dexamethasone
8mg IV

Study 2
(Abdelmalak et
al., 2013)

Group 4- ND2
control

Overall Outcome

Mean BG
2h

Mean BG
4h

Mean BG
6h

Mean BG
8h

Mean Peak
BG

122.4 ± 28.8

147.6 ± 25.2

158.4 ± 18.0

176.4 ± 25.2

187.2 ± 28.8

129.6 ± 32.4

135.0 ± 18.0

126.0 ± 18.0

129.6 ± 36.0

158.4 ± 30.6

n/a

n/a

n/a

n/a

209.0 ± 66.0

n/a

n/a

n/a

n/a

209.0 ± 72.0

n/a

n/a

n/a

n/a

182.0 ± 41.0

n/a

n/a

n/a

n/a

154.0 ± 45.0
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Study 3
(Tien et al.,
2016)

In non-diabetic patients, the
Group 1- ND maximum BG was higher in
dexamethasone those who received
8mg IV
dexamethasone compared to
those who received
Group 2- ND ondansetron (p = 0.04); the
same conclusion was
ondansetron
exhibited with type 2 diabetic
4mg IV
patients who received
dexamethasone compared to
Group 3- DM those who received
dexamethasone ondansetron (p < 0.01)
8mg IV
Group 4- DM
ondansetron
4mg IV

Study 4
(Purushothaman
et al., 2018)

There was a rise in BG levels
Group 1- DM in both diabetic and
nondiabetic groups who
control
received dexamethasone.
However, this rise was not
Group 2- DM clinically significant with a
dexamethasone range of 10-15 mg/dl from
baseline. BG levels peaked at
4mg IV
T4 in the DM4 group, which
was a statistically significant
Group 3- DM increase from baseline. BG
dexamethasone levels in the DM8 group
8mg IV
peaked at T5. BG levels

115.2 ± 18.0

153.0 ± 28.8

n/a

n/a

163.8 ± 39.6

118.8 ± 23.4

131.4 ± 28.8

n/a

n/a

140.4 ± 25.2

169.2 ± 50.4

187.2 ± 54.0

n/a

n/a

252.0 ± 45.0

145.8 ± 39.6

154.8 ± 37.8

n/a

n/a

192.6 ± 43.2

141.2 ± 25.2

147.3 ± 23.6

146.9 ± 20.8

144.5 ± 20.6

148.0 ± 17.2

149.3 ± 20.6

169.3 ± 21.8

158.0 ± 25.4

151.2 ± 20.8

169.0 ± 17.3

143.3 ± 28.0

166.8 ± 26.0

160.2 ± 16.0

149.1 ± 17.0

168.0 ± 22.4
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peaked for groups ND4 and
Group 4- ND ND8 at T5 and T6,
respectively. At T8, in
control
comparison with the DM8
group, the ND8 group had a
Group 5- ND statistically significant
dexamethasone increase in BG levels.
4mg IV
Group 6- ND
dexamethasone
8mg IV

102.1 ± 13.4

100.9 ± 23.7

103.7 ± 15.3

100.3 ± 15.0

105.0 ± 23.6

104.9 ± 18.9

126.6 ± 23.3

124.3 ± 24.5

114.6 ± 21.3

133.0 ± 20.4

104.8 ± 15.3

129.4 ± 25.3

139.9 ± 27.9

131.1 ± 28.1

140.0 ± 23.2

Note. DM – diabetic group, ND – nondiabetic group. BG = mg/dl

